rs2059807 — INSR INSR intronic variant

Intronic INSR variant associated with PCOS susceptibility and metabolic syndrome risk through altered insulin receptor signaling

See your personal result for INSR

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Insulin Receptor Variant Linked to PCOS and Metabolic Risk

The insulin receptor (INSR) gene encodes the cell-surface receptor that binds insulin and triggers glucose uptake in muscle, fat, and liver. When this signaling cascade11 signaling cascade
The insulin signaling pathway: insulin binds INSR → INSR autophosphorylates → IRS1/IRS2 activation → PI3K/AKT → GLUT4 translocation → glucose enters the cell works efficiently, blood sugar stays stable after meals. rs2059807 is an intronic variant — it does not change the protein directly — but it may alter INSR transcript splicing or expression levels in metabolically relevant tissues, influencing the sensitivity of cells to insulin's signal.

The Mechanism

As an intronic variant, rs2059807 does not produce an amino acid change. Its functional effect is likely regulatory22 regulatory
Intronic variants can create or destroy splice enhancer/silencer motifs, alter transcription factor binding sites within the intron, or influence expression via chromatin looping to nearby enhancers — affecting how much INSR protein is produced or which splice isoforms predominate. The INSR gene generates two major isoforms (IR-A and IR-B) through alternative splicing of exon 11; altered isoform balance shifts downstream signaling toward mitogenic versus metabolic outputs. Even modest reductions in insulin receptor abundance or signaling fidelity can drive compensatory hyperinsulinemia — the hallmark of insulin resistance.

The Evidence

The strongest evidence for rs2059807 comes from the PCOS field:

  • A meta-analysis of four independent studies33 meta-analysis of four independent studies
    Feng et al. The association between polymorphism of INSR and polycystic ovary syndrome: a meta-analysis. Int J Mol Sci, 2015     encompassing 11,683 PCOS cases and 12,830 controls confirmed that rs2059807 is a robust susceptibility locus for PCOS in multiple ethnic cohorts.

  • A study in 2,082 Han Chinese women with PCOS44 study in 2,082 Han Chinese women with PCOS
    Tian et al. PCOS-GWAS Susceptibility Variants in THADA, INSR, TOX3, and DENND1A Are Associated With Metabolic Syndrome or Insulin Resistance. Front Endocrinol, 2020     showed that G-allele carriers (AG+GG) had a 27% increased risk of metabolic syndrome compared to AA homozygotes (OR 1.27, P=0.023), independent of age.

  • In 253 Indian women with PCOS55 253 Indian women with PCOS
    Dakshinamoorthy et al. Association of GWAS identified INSR variants (rs2059807 & rs1799817) with polycystic ovarian syndrome in Indian women. Int J Biol Macromol, 2020    , rs2059807 minor-allele carriers showed elevated LH (6.32 vs 4.97 mIU/mL), higher estradiol (116 vs 65 pg/mL), and lower HDL-cholesterol (50 vs 64 mg/dL) compared to controls — a hormonal and metabolic profile consistent with impaired insulin signaling.

  • In the Framingham Heart Study (n=1,475 controls, 396 cases)66 Framingham Heart Study (n=1,475 controls, 396 cases)
    Parekh et al. Insulin receptor variants and obesity-related cancers in the Framingham Heart Study. Cancer Causes Control, 2015    , rs2059807 was the most significant INSR variant associated with obesity-related cancers (colorectal OR 1.5, breast OR 1.29), highlighting broader metabolic consequences beyond reproductive phenotypes.

The overall evidence is replicated across multiple populations and phenotypes but remains at the moderate tier — effect sizes are modest (OR 1.2–1.3 range), and the causal mechanism (exactly how this intronic variant alters INSR function) has not been characterized at the molecular level.

Practical Actions

For G-allele carriers, the primary concern is insulin resistance and its downstream consequences: elevated fasting glucose, dyslipidemia (especially low HDL and elevated triglycerides), and — in women — PCOS susceptibility. The actionable levers are those that directly improve insulin sensitivity through mechanisms independent of lifestyle platitudes: specifically, monitoring fasting insulin and glucose to detect early compensatory hyperinsulinemia, and choosing dietary patterns (low-glycemic, lower refined carbohydrate) that reduce insulin demand on a receptor that may be less abundant or responsive.

GG homozygotes, who carry the greatest G-allele dose, benefit most from periodic fasting insulin testing — a marker rarely ordered in routine care but highly informative for detecting insulin resistance before fasting glucose rises above normal.

Interactions

The variant interacts with the broader insulin signaling network: IRS1 rs1801278 and TCF7L2 rs7903146 (energy-weight category) affect overlapping pathways. Individuals carrying G here alongside TCF7L2 T alleles face compounded impairment of glucose-stimulated insulin secretion and peripheral insulin sensitivity.

Genotype Interpretations

What each possible genotype means for this variant.

AA Typical Insulin Signaling Normal

Reference genotype — typical INSR expression and insulin sensitivity

You carry two copies of the reference A allele at rs2059807 in the INSR gene. This is the genotype associated with typical insulin receptor signaling in population studies. About 15% of people of European descent share this exact genotype (it is more common in East Asians, where roughly 46% are AA).

Your INSR variant profile does not add to baseline metabolic syndrome or PCOS susceptibility from this locus.

AG One Risk Allele Intermediate

One G allele — modestly elevated metabolic syndrome and PCOS risk

The biological mechanism is not fully characterized, but the G allele at this intronic position may reduce INSR transcript abundance or shift isoform balance, modestly impairing insulin receptor signaling fidelity. In the setting of positive energy balance or a high-glycemic diet, even a modest reduction in insulin receptor efficiency can drive compensatory hyperinsulinemia — elevating fasting insulin before fasting glucose rises.

In the Tian et al. 2020 study (2,082 Han Chinese women with PCOS), the dominant model (AG+GG vs AA) showed OR 1.27 for metabolic syndrome.

For women, this variant is specifically associated with PCOS susceptibility in multiple GWAS datasets — heightening the relevance of monitoring hormonal and metabolic markers.

GG Two Risk Alleles High Risk

Two G alleles — elevated metabolic syndrome and PCOS risk

The GG genotype means every copy of the INSR gene carries the G allele, maximizing any effect on INSR expression or splicing that this intronic variant confers. In the Tian et al. 2020 study in Han Chinese women with PCOS, the combined AG+GG group showed OR 1.27 for metabolic syndrome; GG homozygotes were not analyzed separately due to sample size, but additive genetic models predict greater risk for GG than AG.

Fasting hyperinsulinemia — where insulin rises to compensate for reduced receptor sensitivity — is the key early metabolic marker. Standard fasting glucose can remain normal for years while fasting insulin is already elevated and driving adverse effects (stimulating LH secretion, promoting androgen production in the ovaries, accelerating hepatic lipogenesis).